MAPK7 and carcinoma: Nuclear ERK5 expression is an independent prognostic marker in PCa, associated with worse outcomes and transition to hormone insensitive disease, whereas ERK5 cytoplasmic expression correlated with the presence of bone metastases, extracapsular disease, and high-grade carcinomas, as measured by Gleason score [83].